首页 | 本学科首页   官方微博 | 高级检索  
     


Time to disease progression in children with relapsed or refractory neuroblastoma treated with ABT‐751: A report from the Children's Oncology Group (ANBL0621)
Authors:Elizabeth Fox MD  Yael P. Mosse' MD  Holly M. Meany MD  James G. Gurney PhD  Geetika Khanna MBBS  MS  Hollie A. Jackson MD  Gary Gordon MD  Suzanne Shusterman MD  Julie R. Park MD  Susan L. Cohn MD  Peter C. Adamson MD  Wendy B. London PhD  John M. Maris MD  Frank M. Balis MD
Affiliation:1. The Children's Hospital of Philadelphia, , Philadelphia, Pennsylvania;2. Children's National Medical Center, , Washington, District of Columbia;3. University of Memphis School of Public Health and St Jude Children's Research Hospital, , Memphis, Tennessee;4. Washington University School of Medicine, , St Louis, Missouri;5. Children's Hospital of Los Angeles, , Los Angeles, California;6. Abbott Laboratories, , Abbott Park, Illinois;7. Boston Children's Hospital and Dana‐Farber Harvard Cancer Center, , Boston, Massachusetts;8. Seattle Children's Hospital, , Seattle, Washington;9. University of Chicago, , Chicago, Illinois;10. Children Oncology Group Statistics and Data Center, , Gainesville, Florida
Abstract:
Keywords:childhood cancer  clinical trial  microtubule inhibitor  neuroblastoma  time to progression
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号